Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7006 to 7020 of 7690 results

  1. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued [GID-TA10668]

    Technology appraisal guidance
    Discontinued

  3. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued [GID-TA10737]

    Technology appraisal guidance
    Discontinued

  4. Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after platinum-based chemotherapy TS ID 11801

    Discontinued [GID-TA11180]

    Technology appraisal guidance
    Discontinued

  5. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

    Technology appraisal guidance
    Discontinued

  6. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued [GID-TA10531]

    Technology appraisal guidance
    Discontinued

  7. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued

  9. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued [GID-TA10382]

    Technology appraisal guidance
    Discontinued

  10. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued [GID-TAG332]

    Technology appraisal guidance
    Discontinued

  11. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued [GID-TAG418]

    Technology appraisal guidance
    Discontinued

  12. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued [GID-TA10337]

    Technology appraisal guidance
    Discontinued

  13. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

    Technology appraisal guidance
    Discontinued

  14. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued [GID-TAG397]

    Technology appraisal guidance
    Discontinued

  15. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued [GID-TA10159]

    Technology appraisal guidance
    Discontinued